Cationic Lipid Compound and Composition for Delivery of Nucleic Acids and Use Thereof
US-2024360072-A1 · Oct 31, 2024 · US
Prodrugs of fumarates and their use in treating various diseases
US10117846B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10117846-B2 |
| Application number | US-201715704219-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 14, 2017 |
| Priority date | Mar 14, 2013 |
| Publication date | Nov 6, 2018 |
| Grant date | Nov 6, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.
First claim
Opening claim text (preview).
What is claimed: 1. A pharmaceutical composition comprising a compound of Formula (Ia), or a pharmaceutically acceptable salt thereof: wherein: R 1 is unsubstituted C 1 -C 6 alkyl; L a is unsubstituted C 1 -C 6 alkyl linker; and R 2 is H, unsubstituted C 1 -C 6 alkyl, unsubstituted C 2 -C 6 alkenyl, or unsubstituted C 2 -C 6 alkynyl; and a pharmaceutically acceptable carrier. 2. The composition of claim 1 , wherein R 1 is methyl. 3. The composition of claim 1 , wherein L a is an unsubstituted C 1 -C 3 alkyl. 4. The composition of claim 3 , wherein L a is an unsubstituted C 2 alkyl. 5. The composition of claim 1 , wherein R 2 is an unsubstituted C 1 -C 6 alkyl, unsubstituted C 2 -C 6 alkenyl, or unsubstituted C 2 -C 6 alkynyl. 6. The composition of claim 5 , wherein R 2 is an unsubstituted C 1 -C 6 alkyl. 7. The composition of claim 6 , wherein R 2 is an unsubstituted C 1 -C 3 alkyl. 8. The composition of claim 7 , wherein R 2 is an unsubstituted C 1 -C 2 alkyl. 9. The composition of claim 8 , wherein R 2 is methyl. 10. The composition of claim 1 , wherein the compound of Formula (Ia) has the structure: or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antipsoriatics · CPC title
Drugs for disorders of the nervous system · CPC title
Halogen atoms or nitro radicals · CPC title
with hetero atoms directly attached to the ring nitrogen atom · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10117846B2 cover?
- The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.
- Who is the assignee on this patent?
- Alkermes Pharma Ireland Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07C229/16. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).